FDA Review of Safety Issues with the Use of Hydroxychloroquine and Chloroquine to Treat Hospitalized Patients with COVID-19 | NLM

Disaster Information Management Research Center | NLM

FDA Review of Safety Issues with the Use of Hydroxychloroquine and Chloroquine to Treat Hospitalized Patients with COVID-19

05/19/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 5/19/2020. The purpose of this 15-page review is for the Division of Pharmacovigilance II to provide the Division of Antiviral Drug Products a high-level overview of the postmarketing safety data related to the use of hydroxychloroquine and chloroquine in the setting of coronavirus disease 2019 (COVID-19). It identifies two emerging safety signals. (PDF)